Indivior Must Disband Suboxone Sales Force, Implement Executive Pay Recoupment Program
Executive Summary
$600m settlement with DOJ over Suboxone marketing includes corporate integrity agreement and exclusion of subsidiary from government health programs. Indivior also agrees to pay $10m to FTC and be enjoined from future antitrust violations.
You may also be interested in...
Biogen Agrees To One Of Largest FCA Settlements Without DOJ Intervention
Company to pay $900m to resolve claims it paid kickbacks to physicians to induce them to prescribe its multiple sclerosis drugs. Whistleblower sought damages based on the number of prescriptions written after a healthcare provider received a kickback from Biogen.
Dr Reddy’s Gets $72m Payout From Suboxone Settlement
Dr Reddy’s is in line for a $72m payout after settling US patent and antitrust litigation over Suboxone with Indivior.
Will FTC Injunction Against Shkreli’s Company Deter Brands From Pursuing Anti-Generic Actions?
Other companies have largely halted practices at issue in the ‘diabolical anticompetitive plan’ undertaken by Shkreli’s former firm. FTC did not challenge the price hike for Daraprim itself, but did cite an effort to block release of sales data and other tactics to discourage generics.